groene appel schreef op 20 december 2021 15:29:
Celyad Oncology (NASDAQ:CYAD) Upgraded to “Buy” at Zacks Investment Research December 19, 2021 ETF Daily News Team
Celyad Oncology SA logoZacks Investment Research upgraded shares of Celyad Oncology (NASDAQ:CYAD) from a hold rating to a buy rating in a report published on Wednesday, Zacks.com reports. The firm currently has $4.75 price target on the stock.
According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
Other analysts also recently issued research reports about the company. Jonestrading reiterated a hold rating on shares of Celyad Oncology in a research note on Friday, August 20th. HC Wainwright decreased their price target on Celyad Oncology from $15.00 to $13.00 and set a buy rating for the company in a research note on Friday, December 10th.
CYAD opened at $4.17 on Wednesday. The stock has a 50-day moving average of $4.28 and a 200-day moving average of $4.50. Celyad Oncology has a 52-week low of $3.53 and a 52-week high of $9.26. The company has a current ratio of 0.97, a quick ratio of 1.42 and a debt-to-equity ratio of 0.10.
A hedge fund recently bought a new stake in Celyad Oncology stock. Endurant Capital Management LP bought a new stake in shares of Celyad Oncology SA (NASDAQ:CYAD) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 160,691 shares of the company’s stock, valued at approximately $845,000. Endurant Capital Management LP owned 1.04% of Celyad Oncology as of its most recent SEC filing. 1.83% of the stock is currently owned by institutional investors.
About Celyad Oncology
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.